HLA-B17 and the HLA-A1, B17 haplotype in acute myelogenous leukemia. Academic Article uri icon

Overview

abstract

  • Seventy-nine Caucasians with acute myelogenous leukemia (AML) were genotyped to determine whether AML, the induction of remission or patient survival were associated with particular HLA phenotypes or haplotypes. HLA-B17 and B27 were increased in AML patients over 40 years of age. Combined analysis of four independent studies indicates that HLA-B17 is significantly but weakly associated with AML, relative risk = 1.48 (.01 less than P less than .025). The A1, B17 and Aw24, Bw35 haplotypes occurred more frequently in the AML group as compared to racial and geographic controls (uncorrected P = 0.0068 and 0.0098, respectively Fisher's Exact Test). Induction of remission occurred less frequently in patients with the B17 phenotype as compared to patients lacking this antigen (P = 0.047). Patient survival was associated with remission status (P = 0.002) but was not significantly associated with particular HLA phenotypes or haplotypes. These results indicate that a gene or genes in the HLA-B region of the major histocompatibility complex can influence susceptibility to AML and also the response to chemotherapy.

publication date

  • August 1, 1979

Research

keywords

  • HLA Antigens
  • Leukemia, Myeloid, Acute

Identity

Scopus Document Identifier

  • 0018647895

Digital Object Identifier (DOI)

  • 10.1111/j.1399-0039.1979.tb00828.x

PubMed ID

  • 291140

Additional Document Info

volume

  • 14

issue

  • 2